Related Experiment Videos

Consistency of ss-blocker effect across various subgroups with heart failure: insights from the MERIT-HF trial

John Wikstrand1, Jalal K Ghali, Sydney Goldstein

  • 1Sahlgrenska University Hospital, SE 413 45 Göteborg, Sweden. john.wikstrand@wlab.gu.se

Postgraduate Medicine
|August 12, 2009
PubMed

Insights

Beta-blockers, including metoprolol succinate, significantly reduce mortality and hospitalizations in patients with chronic heart failure. These findings are consistent across various patient risk groups, confirming their therapeutic benefit.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Recent trials like MERIT-HF, CIBIS-II, and COPERNICUS evaluated beta-blockers in heart failure.
  • These studies consistently demonstrated reduced mortality and hospitalizations for worsening heart failure.

Purpose of the Study:

  • To review the consistency of beta-blocker effects in heart failure.
  • To analyze these effects across predefined and post hoc risk subgroups within the MERIT-HF trial.

Main Methods:

  • Review of survival trial data, focusing on MERIT-HF.
  • Analysis of metoprolol succinate's efficacy in patients with NYHA classes II-IV heart failure and ejection fraction ≤40%.

Main Results:

  • Consistent reduction in mortality and hospitalizations for worsening heart failure observed across trials.
  • MERIT-HF specifically investigated extended-release metoprolol succinate in heart failure patients.

Conclusions:

  • Beta-blockers demonstrate consistent benefits in reducing mortality and hospitalizations in heart failure.
  • Metoprolol succinate is effective in managing chronic heart failure across diverse patient risk profiles.

Related Concept Videos

Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Heart Failure III: Clinical Manifestations01:26

Heart Failure III: Clinical Manifestations

Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...